Human Gene EGFR (uc011kcp.1)
|
|
Sequence and Links to Tools and Databases
|
|
Primer design for this transcript
|
|
Genetic Association Studies of Complex Diseases and Disorders
|
|
Genetic Association Database (archive): EGFR
CDC HuGE Published Literature: EGFR
Positive Disease Associations: Acute Coronary Syndrome|
, anaplastic astrocytoma; glioblastoma multiforme
, asthma
, Body Height
, brain cancer
, Carcinoma, Non-Small-Cell Lung|Exanthema|Lung Neoplasms
, Cardiomyopathy, Dilated|
, colorectal cancer
, glioblastoma multiforme
, Glioma
, head and neck cancer
, lung cancer
, lupus erythematosus
, pancreatic cancer
, polycystic kidney disease
, prostate cancer
, prostatic hyperplasia
, radiation sensitivity
, rectal cancer
, Respiratory Function Tests
Related Studies: - Acute Coronary Syndrome|
Lin-Bo Gao , et al. BMC medical genetics 2008 9():74, R497K polymorphism in epidermal growth factor receptor gene is associated with the risk of acute coronary syndrome., BMC medical genetics 2008 9():74.
[PubMed 18664296]
R497K polymorphism of the EGFR gene is significantly associated with the risk of ACS.
- anaplastic astrocytoma; glioblastoma multiforme
Smith, J. S. et al. 2001, PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme., Journal of the National Cancer Institute. 2001 Aug;93(16):1246-56.
[PubMed 11504770]
PTEN mutation and EGFR amplification are important prognostic factors in patients with anaplastic astrocytoma and in older patients with glioblastoma multiforme, respectively.
- asthma
Wang, X. et al. 2006, Polymorphism of egfr Intron1 is Associated with Susceptibility and Severity of Asthma, J Asthma 2006 43(9) 711-5.
[PubMed 17092854]
  more ... click here to view the complete list
| |
|
|
MalaCards Disease Associations
|
|
MalaCards Gene Search: EGFR
Diseases sorted by gene-association score: inflammatory skin and bowel disease, neonatal, 2* (1280), lung cancer* (547), giant cell glioblastoma* (371), gliosarcoma* (355), neonatal inflammatory skin and bowel disease* (350), cowden syndrome 1* (283), lung cancer, egfr-related* (100), glioblastoma (60), glioblastoma multiforme (51), brain cancer (45), lung squamous cell carcinoma (34), adenosquamous carcinoma (31), squamous cell carcinoma (28), lung cancer susceptibility 3 (27), adenocarcinoma (26), vulva cancer (25), oral cavity cancer (24), paronychia (24), squamous cell carcinoma, head and neck (24), pleomorphic carcinoma (23), esophageal basaloid squamous cell carcinoma (22), brain stem glioma (21), malignant glioma (21), oligodendroglioma (20), pancreatic cancer (19), superior vena cava syndrome (18), orbital lymphangioma (18), papillary glioneuronal tumor (18), colorectal cancer (17), bronchiolo-alveolar adenocarcinoma (17), cervical adenosquamous carcinoma (15), spinal chordoma (15), breast cancer (14), breast intraductal proliferative lesion (14), malignant peritoneal mesothelioma (13), astrocytoma (13), grade iii astrocytoma (12), exanthem (12), endometrial cancer (12), mucoepidermoid carcinoma (12), breast ductal carcinoma (12), glioma (11), transitional cell carcinoma (11), brain glioma (11), lung benign neoplasm (11), ductal carcinoma in situ (10), salivary gland cancer (10), brain ependymoma (10), prostate cancer 1 (10), peritoneal mesothelioma (10), penile cancer (10), mammary paget's disease (9), interstitial lung disease (9), recurrent respiratory papillomatosis (9), uterine carcinosarcoma (9), progesterone-receptor negative breast cancer (9), ovarian cancer, somatic (9), small intestinal adenocarcinoma (9), trichomegaly (9), nasopharyngeal carcinoma (9), irinotecan toxicity (9), microglandular adenosis (9), pulmonary blastoma (9), gliomatosis cerebri (9), cell type cancer (9), pancreatic ductal adenocarcinoma (8), gallbladder adenocarcinoma (8), malignant peripheral nerve sheath tumor (8), oral squamous cell carcinoma (8), mucinous adenocarcinoma (8), gallbladder cancer (7), ependymoma (7), inflammatory breast carcinoma (7), breast adenocarcinoma (7), oral cancer (7), li-fraumeni syndrome (7), large cell neuroendocrine carcinoma (7), tubular adenocarcinoma (7), basaloid squamous cell carcinoma (7), left ventricular outflow tract obstruction (7), large cell carcinoma (7), pre-malignant neoplasm (7), prostate cancer (7), troyer syndrome (7), doxorubicin induced cardiomyopathy (7), hepatoid adenocarcinoma (7), intrahepatic cholangiocarcinoma (7), hepatitis c virus (7), adenosquamous cell lung carcinoma (7), chordoma (6), nail disease (6), larynx cancer (6), placental site trophoblastic tumor (6), cervical adenocarcinoma (6), cervical squamous cell carcinoma (6), luminal breast carcinoma (6), colorectal adenocarcinoma (6), malignant pleural mesothelioma (6), breast scirrhous carcinoma (6), small cell carcinoma (6), oncocytic breast carcinoma (6), intracystic papillary adenoma (6), gastrointestinal system cancer (6), in situ pulmonary adenocarcinoma (6), soft tissue sarcoma (6), asbestos-related lung carcinoma (6), breast squamous cell carcinoma (6), thymus cancer (6), adamantinoma of long bones (5), endometrial adenocarcinoma (5), villous adenocarcinoma (5), gastric adenosquamous carcinoma (5), hidradenocarcinoma (5), oropharynx cancer (5), primary peritoneal carcinoma (5), lipid-rich carcinoma (5), breast metaplastic carcinoma (5), prostatic hypertrophy (5), hepatitis e (5), in situ carcinoma (5), ethmoid sinus cancer (5), ethmoid sinus adenocarcinoma (5), clear cell renal cell carcinoma (5), breast adenoid cystic carcinoma (4), lung adenoid cystic carcinoma (4), tonsil squamous cell carcinoma (4), esophageal cancer (4), familial renal papillary carcinoma (4), acneiform dermatitis (4), tonsil cancer (4), geographic tongue (4), kidney cancer (3), differentiated thyroid carcinoma (3), diarrhea (3), stomach cancer (3), renal cell carcinoma (2), urinary bladder cancer (2), small cell cancer of the lung, somatic (2), bladder cancer, somatic (2), papilloma (2), gastrointestinal stromal tumor (2), reproductive organ cancer (1), female reproductive organ cancer (1), pharynx cancer (1), pancreas adenocarcinoma (1), gastric cancer, somatic (1) * = Manually curated disease association
| |
|
|
Comparative Toxicogenomics Database (CTD)
|
|
RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
|
|
Microarray Expression Data
|
|
Press "+" in the title bar above to open this section.
| |
|
|
Orthologous Genes in Other Species
|
|
Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
Mouse | Rat | Zebrafish | D. melanogaster | C. elegans | S. cerevisiae |
No ortholog | No ortholog | No ortholog | No ortholog | No ortholog | No ortholog |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
|
| |
|
|
Descriptions from all associated GenBank mRNAs
|
|
U95089 - Human truncated epidermal growth factor receptor-like protein precursor mRNA, complete cds. BC094761 - Homo sapiens epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), mRNA (cDNA clone MGC:104637 IMAGE:30528231), complete cds. FW403750 - NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOFF. FW403749 - NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOFF. FW403751 - NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOFF. FW403748 - NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOFF. HQ912715 - Homo sapiens epidermal growth factor receptor mRNA, complete cds, alternatively spliced. LP830504 - Sequence 6 from Patent EP3211090. AF125253 - Homo sapiens truncated epidermal growth factor receptor precursor (EGFR) mRNA, complete cds. U48722 - Human epidermal growth factor receptor precursor (EGFR) mRNA, complete cds. X00588 - Human mRNA for precursor of epidermal growth factor receptor. BC070081 - Homo sapiens cDNA clone IMAGE:30346915, containing frame-shift errors. AK225422 - Homo sapiens mRNA for epidermal growth factor receptor isoform a variant, clone: HRC11519. K03193 - Homo sapiens aberrant epidermal growth factor receptor (EGFR) mRNA, complete cds. AB209442 - Homo sapiens mRNA for epidermal growth factor receptor isoform a variant protein. AY550966 - Homo sapiens cell growth inhibiting protein 40 mRNA, complete cds. DQ088980 - Homo sapiens cell proliferation-inducing protein 61 mRNA, complete cds. AK290352 - Homo sapiens cDNA FLJ76780 complete cds, highly similar to Homo sapiens epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) (EGFR), transcript variant 1, mRNA. GU255993 - Homo sapiens epidermal growth factor receptor variant A (EGFR) mRNA, EGFR-S allele, complete cds, alternatively spliced. KJ904454 - Synthetic construct Homo sapiens clone ccsbBroadEn_13848 EGFR gene, encodes complete protein. AY698024 - Homo sapiens epidermal growth factor receptor short isoform (EGFR) mRNA, complete cds. AY698023 - Homo sapiens epidermal growth factor receptor (EGFR) mRNA, partial cds. AB528482 - Synthetic construct DNA, clone: pF1KB4458, Homo sapiens EGFR gene for epidermal growth factor receptor, without stop codon, in Flexi system. AK294750 - Homo sapiens cDNA FLJ55514 complete cds, highly similar to Epidermal growth factor receptor precursor (EC 2.7.10.1). AH006650 - Homo sapiens chromosome 7 epidermal growth factor receptor (EGFR) gene, partial cds. X00663 - Human mRNA fragment for epidermal growth factor (EGF) receptor. BC118665 - Homo sapiens epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), mRNA (cDNA clone IMAGE:40017083), complete cds. BC128419 - Homo sapiens epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian), mRNA (cDNA clone IMAGE:40117840), partial cds. HQ999997 - Homo sapiens epidermal growth factor receptor (EGFR) mRNA, partial cds. EF210210 - Homo sapiens epidermal growth factor receptor variant EX12_14del (EGFR) mRNA, partial cds, alternatively spliced. EF210211 - Homo sapiens epidermal growth factor receptor variant EX12_15del (EGFR) mRNA, partial cds, alternatively spliced. HQ730875 - Homo sapiens epidermal growth factor receptor variant (EGFR) mRNA, partial sequence. MP096454 - Sequence 329 from Patent EP3436584. MP096455 - Sequence 330 from Patent EP3436584. MP096456 - Sequence 331 from Patent EP3436584. MP096457 - Sequence 332 from Patent EP3436584. MP096458 - Sequence 333 from Patent EP3436584. MP096459 - Sequence 334 from Patent EP3436584. MP096460 - Sequence 335 from Patent EP3436584. MP096461 - Sequence 336 from Patent EP3436584. MP096462 - Sequence 337 from Patent EP3436584. MP096463 - Sequence 338 from Patent EP3436584. MP096464 - Sequence 339 from Patent EP3436584. MP096465 - Sequence 340 from Patent EP3436584. MP096466 - Sequence 341 from Patent EP3436584. MP096467 - Sequence 342 from Patent EP3436584. MP096468 - Sequence 343 from Patent EP3436584. MP096469 - Sequence 344 from Patent EP3436584. MP096470 - Sequence 345 from Patent EP3436584. MP096471 - Sequence 346 from Patent EP3436584. MP096472 - Sequence 347 from Patent EP3436584. MP096473 - Sequence 348 from Patent EP3436584. MP096474 - Sequence 349 from Patent EP3436584. MP096475 - Sequence 350 from Patent EP3436584. MP096476 - Sequence 351 from Patent EP3436584. MP096477 - Sequence 352 from Patent EP3436584. MP096478 - Sequence 353 from Patent EP3436584. MP096479 - Sequence 354 from Patent EP3436584. MP096480 - Sequence 355 from Patent EP3436584. MP096481 - Sequence 356 from Patent EP3436584. MP096482 - Sequence 357 from Patent EP3436584. MP096492 - Sequence 367 from Patent EP3436584. MP096493 - Sequence 368 from Patent EP3436584. MP096494 - Sequence 369 from Patent EP3436584. MP096495 - Sequence 370 from Patent EP3436584. MP096496 - Sequence 371 from Patent EP3436584. MP096497 - Sequence 372 from Patent EP3436584. MP096498 - Sequence 373 from Patent EP3436584. MP096499 - Sequence 374 from Patent EP3436584. MP096500 - Sequence 375 from Patent EP3436584. MP096501 - Sequence 376 from Patent EP3436584. LY639852 - KR 1020180124142-A/404: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639853 - KR 1020180124142-A/405: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639854 - KR 1020180124142-A/406: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639855 - KR 1020180124142-A/407: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639856 - KR 1020180124142-A/408: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639857 - KR 1020180124142-A/409: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639858 - KR 1020180124142-A/410: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639859 - KR 1020180124142-A/411: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639860 - KR 1020180124142-A/412: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639861 - KR 1020180124142-A/413: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639862 - KR 1020180124142-A/414: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639863 - KR 1020180124142-A/415: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639864 - KR 1020180124142-A/416: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639865 - KR 1020180124142-A/417: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639866 - KR 1020180124142-A/418: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639867 - KR 1020180124142-A/419: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639868 - KR 1020180124142-A/420: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639869 - KR 1020180124142-A/421: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639870 - KR 1020180124142-A/422: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639871 - KR 1020180124142-A/423: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639872 - KR 1020180124142-A/424: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639873 - KR 1020180124142-A/425: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639874 - KR 1020180124142-A/426: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639875 - KR 1020180124142-A/427: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639876 - KR 1020180124142-A/428: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639877 - KR 1020180124142-A/429: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639878 - KR 1020180124142-A/430: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639879 - KR 1020180124142-A/431: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639880 - KR 1020180124142-A/432: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639890 - KR 1020180124142-A/442: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639891 - KR 1020180124142-A/443: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639892 - KR 1020180124142-A/444: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639893 - KR 1020180124142-A/445: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639894 - KR 1020180124142-A/446: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639895 - KR 1020180124142-A/447: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639896 - KR 1020180124142-A/448: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639897 - KR 1020180124142-A/449: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639898 - KR 1020180124142-A/450: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. LY639899 - KR 1020180124142-A/451: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122568 - JP 2019513371-A/404: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122569 - JP 2019513371-A/405: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122570 - JP 2019513371-A/406: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122571 - JP 2019513371-A/407: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122572 - JP 2019513371-A/408: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122573 - JP 2019513371-A/409: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122574 - JP 2019513371-A/410: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122575 - JP 2019513371-A/411: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122576 - JP 2019513371-A/412: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122577 - JP 2019513371-A/413: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122578 - JP 2019513371-A/414: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122579 - JP 2019513371-A/415: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122580 - JP 2019513371-A/416: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122581 - JP 2019513371-A/417: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122582 - JP 2019513371-A/418: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122583 - JP 2019513371-A/419: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122584 - JP 2019513371-A/420: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122585 - JP 2019513371-A/421: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122586 - JP 2019513371-A/422: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122587 - JP 2019513371-A/423: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122588 - JP 2019513371-A/424: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122589 - JP 2019513371-A/425: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122590 - JP 2019513371-A/426: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122591 - JP 2019513371-A/427: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122592 - JP 2019513371-A/428: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122593 - JP 2019513371-A/429: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122594 - JP 2019513371-A/430: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122595 - JP 2019513371-A/431: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122596 - JP 2019513371-A/432: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122606 - JP 2019513371-A/442: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122607 - JP 2019513371-A/443: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122608 - JP 2019513371-A/444: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122609 - JP 2019513371-A/445: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122610 - JP 2019513371-A/446: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122611 - JP 2019513371-A/447: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122612 - JP 2019513371-A/448: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122613 - JP 2019513371-A/449: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122614 - JP 2019513371-A/450: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF. MB122615 - JP 2019513371-A/451: NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF.
| |
|
|
Biochemical and Signaling Pathways
|
|
Other Names for This Gene
|
|
Alternate Gene Symbols: EF210211 UCSC ID: uc011kcp.1 RefSeq Accession: NM_005228
| |
|
|
Gene Model Information
|
|
category:
| nearCoding
| nonsense-mediated-decay:
| no
| RNA accession:
| EF210211.1
|
exon count:
| 4 | CDS single in 3' UTR:
| no
| RNA size:
| 256 |
ORF size:
| 0 | CDS single in intron:
| no
| Alignment % ID:
| 100.00 |
txCdsPredict score:
| 167.00 | frame shift in genome:
| no
| % Coverage:
| 100.00 |
has start codon:
| no
| stop codon in genome:
| no
| # of Alignments:
| 1 |
has end codon:
| no
| retained intron:
| no
| # AT/AC introns
| 0 |
selenocysteine:
| no
| end bleed into intron:
| 0 | # strange splices:
| 0 |
|
Click here
for a detailed description of the fields of the table above.
| |
|
|
Methods, Credits, and Use Restrictions
|
|
Click here
for details on how this gene model was made and data restrictions if any.
| |
|
|
|